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Primary brain tumors form an important public health pro-
blem. There were more than 66,000 cases diagnosed in the
US in 2012 with 13,700 deaths. The most malignant pri-
mary brain tumor in adults - Glioblastoma multiforme
(GBM) - is extremely aggressive and invasive cancer, diffi-
cult to surgery with high resistance to standard radiother-
apy and chemotherapy. The median survival of patient with
GBM is 12.1 – 14.6 months and only 3-5% of patients sur-
vive longer than 3 years. There is an urgent need for further
progress in neurooncology in the area of tumor early diag-
nosis, accurate characterization and more efficient treat-
ment. The unprecedented progress of recent years in all
omics disciplines such as genomics, transcriptomics, pro-
teomics and others together with the improvements of
bioinformatics technologies provides new opportunities in
current brain cancer research. The human genome was
fully sequenced and the improvements of sequencing meth-
ods have lately permitted genome-wide association studies
in human cancers including primary brain tumors. The
new milestones of oncogenesis - abnormalities in signaling
pathways, tumor microenvironment, pathological angio-
genesis, cancer metabolism and others – were uncovered
over the past decade. Currently some novel molecular bio-
markers in neurooncology are emerging that could be used
as a prognostic and predictive factor of the disease. For glio-
blastoma multiforme the most promising biomarker, pro-
moter methylation status of the MGMT gene, helps to
predict the tumor response to standard chemotherapy with
temozolomide. For all astrocytic tumors, there is a strong
prognostic effect of mutations in the fundamental meta-
bolic enzymes - Isocitrate dehydrogenases 1 and 2. Also the
epigenetic changes of cancer genome, glioma cytosine-
guanine island methylator phenotype, show promise like
the prognostic biomarker. For oligodendrogliomas, the
most promising predictive biomarker in relation to the
standard PCV chemotherapy treatment is the loss of
1p/19q due to an unbalanced chromosomal translocation.
There are many other potential markers for primary brain
tumors in research, such as the amount of CD 133 positive
cancer “stem” cells, small non-coding microRNA’s or
tumors gene expression profiles. With the discovery of
novel molecular prognostic and predictive markers for var-
ious brain tumors, the therapy goal is rapidly changing
from treating a class of tumors to the individual therapy
plan for each patient according to the molecular characteri-
zation of the actual tumor, the real philosophy of persona-
lized medicine.
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